ARTICLE
5 April 2022
Mondaq Thought Leadership Award Winner

Celltrion Announces Agreement With Brazilian Government To Supply Infliximab Biosimilar

GP
Goodwin Procter LLP

Contributor

At Goodwin, we partner with our clients to practice law with integrity, ingenuity, agility, and ambition. Our 1,600 lawyers across the United States, Europe, and Asia excel at complex transactions, high-stakes litigation and world-class advisory services in the technology, life sciences, real estate, private equity, and financial industries. Our unique combination of deep experience serving both the innovators and investors in a rapidly changing, technology-driven economy sets us apart.
On March 24, 2022, Celltrion Healthcare announced that it had won a bid to the Brazilian Federal Government to supply a biosimilar version of Remsima® (infliximab), along with bids to 12 Brazilian states.
Brazil Food, Drugs, Healthcare, Life Sciences

On March 24, 2022, Celltrion Healthcare announced that it had won a bid to the Brazilian Federal Government to supply a biosimilar version of Remsima® (infliximab), along with bids to 12 Brazilian states.  According to the company, infliximab will be the third biosmilar product that Celltrion is to supply to the Brazilian market after Celltrion reached agreement in 2021 with the Brazilian Ministry of Health to supply Truxima® (Celltrion's rituximab biosimilar) and Herzuma® (Celltrion's trastuzumab biosimilar).

Dr. HoUng Kim, Ph.D., Head of Medical and Marketing Division at Celltrion Healthcare said that as a result of sales to the Brazilian government and the private sector, Celltrion expects "to achieve approximately two-thirds of the total Brazilian infliximab market."

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More